Department of Cardiology, Beijing Anzhen Hospital Affiliated to the Capital Medical University, Beijing, China.
Angiology. 2012 Jul;63(5):330-5. doi: 10.1177/0003319711418219. Epub 2011 Sep 7.
Although drug-eluting stents (DESs) can decrease the risk of restenosis, this benefit is tempered by a possible increased risk of in-stent thrombosis. We assessed the effects of rapamycin on human umbilical vein endothelial cells (HUVECs) to identify the alterations in gene expression associated with thrombosis. Expression of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) was assessed in HUVECs treated with rapamycin (final concentrations: 1, 10, 100, and 1000 ng/mL) for 24 and 48 hours. Incubation of HUVECs with rapamycin strongly reduced the expression of t-PA in a concentration-dependant manner (P < .05 to < .01). However, the expression of PAI-1 was induced by rapamycin (P < .05 to < .01). The increase in PAI-1 induction was up to 3.3-fold. In conclusion, rapamycin inhibited t-PA and induced PAI-1 expression in HUVECs. This effect may contribute to in-stent thrombosis associated with DESs.
虽然药物洗脱支架 (DES) 可以降低再狭窄的风险,但这一益处受到支架内血栓形成风险增加的影响。我们评估了雷帕霉素对人脐静脉内皮细胞 (HUVEC) 的影响,以确定与血栓形成相关的基因表达变化。用雷帕霉素 (终浓度:1、10、100 和 1000ng/mL) 处理 HUVEC 24 和 48 小时后,评估组织纤溶酶原激活物 (t-PA) 和纤溶酶原激活物抑制剂 1 (PAI-1) 的表达。雷帕霉素以浓度依赖的方式强烈降低 t-PA 的表达 (P<0.05 至 <0.01)。然而,雷帕霉素诱导了 PAI-1 的表达 (P<0.05 至 <0.01)。PAI-1 诱导的增加高达 3.3 倍。总之,雷帕霉素抑制 HUVEC 中的 t-PA 并诱导 PAI-1 表达。这种作用可能与 DES 相关的支架内血栓形成有关。